HomeCompareANEWF vs JNJ

ANEWF vs JNJ: Dividend Comparison 2026

ANEWF yields 95.65% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANEWF wins by $59.29M in total portfolio value
10 years
ANEWF
ANEWF
● Live price
95.65%
Share price
$17.00
Annual div
$16.26
5Y div CAGR
11.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$59.32M
Annual income
$35,561,386.70
Full ANEWF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ANEWF vs JNJ

📍 ANEWF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANEWFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANEWF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANEWF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANEWF
Annual income on $10K today (after 15% tax)
$8,130.00/yr
After 10yr DRIP, annual income (after tax)
$30,227,178.70/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ANEWF beats the other by $30,223,192.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANEWF + JNJ for your $10,000?

ANEWF: 50%JNJ: 50%
100% JNJ50/50100% ANEWF
Portfolio after 10yr
$29.68M
Annual income
$17,783,038.05/yr
Blended yield
59.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ANEWF
No analyst data
Altman Z
0.3
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANEWF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANEWFJNJ
Forward yield95.65%2.13%
Annual dividend / share$16.26$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR11.9%28%
Portfolio after 10y$59.32M$30.3K
Annual income after 10y$35,561,386.70$4,689.40
Total dividends collected$56.76M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ANEWF vs JNJ ($10,000, DRIP)

YearANEWF PortfolioANEWF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$21,403$10,702.91$10,592$272.30+$10.8KANEWF
2$46,857$23,956.36$11,289$357.73+$35.6KANEWF
3$104,987$54,849.56$12,123$472.89+$92.9KANEWF
4$240,858$128,521.66$13,141$629.86+$227.7KANEWF
5$566,070$308,352.63$14,408$846.81+$551.7KANEWF
6$1,363,581$757,885.78$16,021$1,151.60+$1.35MANEWF
7$3,368,272$1,909,240.16$18,122$1,588.22+$3.35MANEWF
8$8,536,164$4,932,113.10$20,930$2,228.20+$8.52MANEWF
9$22,205,482$13,071,786.20$24,792$3,191.91+$22.18MANEWF
10$59,321,252$35,561,386.70$30,274$4,689.40+$59.29MANEWF

ANEWF vs JNJ: Complete Analysis 2026

ANEWFStock

Australia and New Zealand Banking Group Limited provides various banking and financial products and services in Australia and internationally. Its Australia Retail division offers home and personal loans, deposits, and credit cards through the branch network, home loan specialists, contact centers, self-service channels, and third-party brokers, as well as financial planning services. Its Australia Commercial division provides asset financing for small business owners, medium and large commercial customers, high net worth individuals, and family groups. The company's Institutional division offers documentary trade, supply chain and commodity financing, cash management solutions, deposits, payments, and clearing services; loan syndication, loan structuring and execution, project and export finance, debt structuring and acquisition finance, and corporate advisory services, as well as loan products; and risk management services. It serves governments, and global institutional and corporate customers. The company's New Zealand division provides banking and wealth management services to consumer, and private banking and small business banking customers through its Internet and app-based digital solutions, network of branches, mortgage specialists, relationship managers, and contact centers; and traditional relationship banking and financial solutions for small, medium, and large enterprises, agricultural business segments, and government and government-related entities. Its Pacific division offers retail products, and traditional relationship banking and financial solutions. This division serves retail customers, small to medium-sized enterprises, institutional customers, and governments. The company was founded in 1835 and is based in Melbourne, Australia.

Full ANEWF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ANEWF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANEWF vs SCHDANEWF vs JEPIANEWF vs OANEWF vs KOANEWF vs MAINANEWF vs ABBVANEWF vs MRKANEWF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.